NYSE:NVS - Novartis Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $108.50
  • Forecasted Upside: 18.49 %
  • Number of Analysts: 11
  • Breakdown:
  • 2 Sell Ratings
  • 4 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$91.57
▲ +0.49 (0.54%)

This chart shows the closing price for NVS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Novartis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NVS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVS

Analyst Price Target is $108.50
▲ +18.49% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Novartis in the last 3 months. The average price target is $108.50, with a high forecast of $112.00 and a low forecast of $105.00. The average price target represents a 18.49% upside from the last price of $91.57.

This chart shows the closing price for NVS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 11 investment analysts is to hold stock in Novartis. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 1 sell ratings
1/30/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 2 sell ratings
4/29/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 2 sell ratings
7/28/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 2 sell ratings
10/26/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 2 sell ratings
1/24/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 2 sell ratings
4/24/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 2 sell ratings
6/23/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 2 sell ratings
7/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/22/2021Deutsche Bank AktiengesellschaftDowngradeBuy ➝ HoldLow
5/11/2021Morgan StanleyReiterated RatingOverweightLow
4/28/2021JPMorgan Chase & Co.Reiterated RatingUnderweightLow
4/28/2021Oddo BhfUpgradeNeutral ➝ OutperformLow
4/19/2021UBS GroupReiterated RatingBuyLow
3/23/2021Societe GeneraleReiterated RatingBuyLow
3/22/2021Sanford C. BernsteinInitiated CoverageMarket PerformMedium
3/16/2021ArgusReiterated RatingBuy ➝ HoldLow
3/10/2021ArgusDowngradeBuy ➝ HoldLow
2/2/2021Morgan StanleyReiterated RatingOverweightLow
2/1/2021CowenDowngradeOutperform ➝ Market Perform$110.00 ➝ $105.00Low
1/22/2021BarclaysReiterated RatingUnderweightMedium
1/15/2021Deutsche Bank AktiengesellschaftInitiated CoverageBuyLow
1/8/2021Morgan StanleyReiterated RatingOverweightLow
12/3/2020ArgusBoost Price Target$100.00 ➝ $112.00Low
11/25/2020UBS GroupReiterated RatingBuyLow
11/10/2020JPMorgan Chase & Co.Reiterated RatingUnderweightLow
9/29/2020Berenberg BankInitiated CoverageBuyMedium
9/23/2020Oddo BhfDowngradeBuy ➝ NeutralLow
9/10/2020UBS GroupUpgradeNeutral ➝ BuyLow
9/1/2020Morgan StanleyUpgradeEqual Weight ➝ OverweightHigh
8/12/2020JPMorgan Chase & Co.Reiterated RatingUnderweightLow
7/28/2020Morgan StanleyReiterated RatingEqual WeightLow
6/15/2020CitigroupUpgradeNeutral ➝ BuyLow
5/11/2020UBS GroupReiterated RatingNeutralMedium
4/29/2020JPMorgan Chase & Co.Reiterated RatingUnderweightLow
4/29/2020BarclaysReiterated RatingUnderweightLow
4/23/2020Morgan StanleyReiterated RatingEqual WeightLow
4/3/2020The Goldman Sachs GroupReiterated RatingBuy$116.00High
3/10/2020Morgan StanleyUpgradeUnderweight ➝ Equal WeightLow
2/25/2020GuggenheimDowngradeBuy ➝ NeutralHigh
2/17/2020CitigroupDowngradeBuy ➝ NeutralLow
10/25/2019CowenReiterated RatingBuy$100.00Low
8/29/2019Jefferies Financial GroupReiterated RatingBuyLow
7/23/2019ArgusBoost Price TargetBuy$105.00Low
7/23/2019Kepler Capital MarketsDowngradeBuy ➝ HoldLow
7/5/2019JPMorgan Chase & Co.Reiterated RatingSellMedium
4/25/2019Liberum CapitalUpgradeHold ➝ BuyLow
4/24/2019GuggenheimUpgradeNeutral ➝ Buy$79.16Medium
4/10/2019Morgan StanleyDowngradeEqual Weight ➝ Underweight$82.50 ➝ $82.52Low
1/29/2019JPMorgan Chase & Co.Reiterated RatingSellLow
1/16/2019JPMorgan Chase & Co.Reiterated RatingSellLow
1/2/2019JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightMedium
12/20/2018Credit Suisse GroupDowngradeSellLow
12/11/2018Jefferies Financial GroupReiterated RatingBuy ➝ Buy$105.00Low
12/7/2018BarclaysDowngradeEqual Weight ➝ SellLow
12/2/2018CowenUpgradeMarket Perform ➝ Outperform$88.03Low
11/28/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
11/26/2018CowenUpgradeMarket Perform ➝ Outperform$100.00Low
11/16/2018The Goldman Sachs GroupUpgradeNeutral ➝ Conviction-BuyLow
11/6/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
10/23/2018Wolfe ResearchInitiated CoverageOutperformMedium
10/18/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
10/11/2018JPMorgan Chase & Co.Reiterated RatingNeutralHigh
10/10/2018The Goldman Sachs GroupReiterated RatingNeutralMedium
10/8/2018GuggenheimInitiated CoverageNeutral ➝ NeutralLow
9/11/2018BNP ParibasUpgradeUnderperform ➝ NeutralLow
9/11/2018Exane BNP ParibasUpgradeUnderperform ➝ NeutralLow
9/11/2018CitigroupUpgradeNeutral ➝ BuyLow
9/10/2018Bank of AmericaUpgradeUnderperform ➝ Buy$74.71Low
7/19/2018BarclaysUpgradeUnderweight ➝ Equal WeightLow
7/19/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
7/19/2018DZ BankReiterated RatingBuyLow
5/29/2018HSBCDowngradeBuy ➝ HoldLow
5/25/2018Credit Suisse GroupUpgradeUnderperform ➝ NeutralLow
5/17/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
4/20/2018Deutsche Bank AktiengesellschaftReiterated RatingNeutralLow
4/10/2018Deutsche Bank AktiengesellschaftReiterated RatingNeutralLow
4/9/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
1/18/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
1/15/2018UBS GroupReiterated RatingNeutralLow
1/2/2018Nord/LBReiterated RatingNeutralMedium
12/27/2017Nord/LBReiterated RatingNeutralLow
12/6/2017Bank of AmericaDowngradeNeutral ➝ UnderperformLow
10/31/2017JPMorgan Chase & Co.Reiterated RatingNeutralN/A
10/25/2017BarclaysDowngradeEqual Weight ➝ UnderweightN/A
10/24/2017JPMorgan Chase & Co.Reiterated RatingNeutralN/A
10/23/2017SVB LeerinkBoost Price TargetMarket Perform$89.00 ➝ $91.00N/A
10/10/2017JPMorgan Chase & Co.Reiterated RatingNeutralN/A
9/26/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
9/5/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
8/29/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
8/9/2017CowenSet Price TargetHold$90.00Medium
7/26/2017Morgan StanleyUpgradeUnderweight ➝ OverweightLow
7/18/2017CowenReiterated RatingHoldLow
7/17/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
7/11/2017CowenSet Price TargetHold$77.00Low
7/10/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
7/5/2017Credit Suisse GroupDowngradeNeutral ➝ Underperform$82.25Medium
6/22/2017SVB LeerinkReiterated RatingMarket Perform$83.00Low
6/22/2017BarclaysUpgradeUnderweight ➝ Equal WeightLow
6/22/2017JPMorgan Chase & Co.Reiterated RatingNeutralHigh
6/16/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
6/8/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
6/6/2017Morgan StanleyReiterated RatingSellLow
6/2/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
5/30/2017UBS GroupReiterated RatingNeutralN/A
5/24/2017UBS GroupReiterated RatingNeutralN/A
4/18/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
4/5/2017CowenDowngradeOutperform ➝ Market Perform$87.00 ➝ $77.00Low
3/23/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
3/22/2017The Goldman Sachs GroupReiterated RatingNeutralLow
3/14/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
3/9/2017Liberum CapitalInitiated CoverageBuy ➝ BuyLow
3/7/2017BarclaysInitiated CoverageUnderweightN/A
3/7/2017Societe GeneraleUpgradeHold ➝ Buy$73.82 ➝ $74.37N/A
3/7/2017BNP ParibasDowngradeNeutral ➝ UnderperformN/A
1/31/2017ArgusUpgradeHold ➝ BuyN/A
1/25/2017JPMorgan Chase & Co.Reiterated RatingNeutralN/A
1/19/2017JPMorgan Chase & Co.Reiterated RatingNeutralN/A
1/17/2017Berenberg BankDowngradeBuy ➝ HoldN/A
1/11/2017Credit Suisse GroupDowngradeOutperform ➝ NeutralN/A
1/9/2017Deutsche Bank AktiengesellschaftReiterated RatingNeutralN/A
1/3/2017JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralN/A
12/13/2016JPMorgan Chase & Co.Reiterated RatingBuyN/A
11/18/2016JPMorgan Chase & Co.Reiterated RatingBuyN/A
11/10/2016ArgusUpgradeHold ➝ Buy$85.00N/A
10/27/2016Societe GeneraleReiterated RatingHoldN/A
10/24/2016JPMorgan Chase & Co.Reiterated RatingBuyN/A
10/16/2016Jefferies Financial GroupReiterated RatingBuyN/A
10/10/2016JPMorgan Chase & Co.Reiterated RatingBuyN/A
10/10/2016Chardan CapitalLower Price TargetBuy$95.00 ➝ $92.00N/A
9/20/2016Chardan CapitalInitiated CoverageBuy$95.00N/A
9/13/2016JPMorgan Chase & Co.Reiterated RatingBuyN/A
8/25/2016ArgusReiterated RatingHoldN/A
(Data available from 7/23/2016 forward)
Novartis logo
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Read More

Today's Range

Now: $91.57
Low: $91.29
High: $92.06

50 Day Range

MA: $91.07
Low: $87.66
High: $94.15

52 Week Range

Now: $91.57
Low: $77.04
High: $98.52

Volume

1,620,221 shs

Average Volume

1,899,016 shs

Market Capitalization

$209.58 billion

P/E Ratio

23.18

Dividend Yield

2.28%

Beta

0.55

Frequently Asked Questions

What sell-side analysts currently cover shares of Novartis?

The following sell-side analysts have issued stock ratings on Novartis in the last twelve months: Argus, Barclays PLC, Berenberg Bank, Cowen Inc, Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., Morgan Stanley, Oddo Bhf, Sanford C. Bernstein, Societe Generale, and UBS Group AG.
View the latest analyst ratings for NVS.

What is the current price target for Novartis?

2 Wall Street analysts have set twelve-month price targets for Novartis in the last year. Their average twelve-month price target is $108.50, suggesting a possible upside of 17.9%. Argus has the highest price target set, predicting NVS will reach $112.00 in the next twelve months. Cowen Inc has the lowest price target set, forecasting a price of $105.00 for Novartis in the next year.
View the latest price targets for NVS.

What is the current consensus analyst rating for Novartis?

Novartis currently has 2 sell ratings, 4 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NVS, but not buy more shares or sell existing shares.
View the latest ratings for NVS.

What other companies compete with Novartis?

How do I contact Novartis' investor relations team?

Novartis' physical mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company's listed phone number is (161) 324-1111 and its investor relations email address is [email protected] The official website for Novartis is www.novartis.com.